Kim, K., Li, J., Barazia, A., Tseng, A., Youn, S., Abbadessa, G., . . . Cho, J. (2017). ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease. Haematologica.
Chicago ZitierstilKim, Kyungho, et al. "ARQ 092, an Orally-available, Selective AKT Inhibitor, Attenuates Neutrophil-platelet Interactions in Sickle Cell Disease." Haematologica 2017.
MLA ZitierstilKim, Kyungho, et al. "ARQ 092, an Orally-available, Selective AKT Inhibitor, Attenuates Neutrophil-platelet Interactions in Sickle Cell Disease." Haematologica 2017.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.